Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema

Volume: 11, Issue: 1
Published: Feb 24, 2021
Abstract
This prospective, open-label, single-arm, non-randomized clinical trial, assessed the efficacy of a 2-year treat-and-extend (T&E) regimen involving intravitreal aflibercept injection (IAI), with the longest treatment interval set to 16 weeks, and adjunct focal/grid laser in diabetic macula edema (DME) patients. We examined 40 eyes (40 adults) with fovea-involving DME from 8 Japanese centers between April 2015 and February 2017. Participants...
Paper Details
Title
Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema
Published Date
Feb 24, 2021
Volume
11
Issue
1
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.